Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987464 · ClinicalTrials.gov registry record · NA
Platform-based Mild Cognitive Impairment (MCI) Trial
A NA study of Mild Cognitive Impairment, sponsored by Allison Gibson.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT03987464: Completed NA study of Mild Cognitive Impairment, sponsored by Allison Gibson.
NCT03987464 is a NA study of Mild Cognitive Impairment that has completed, run by Allison Gibson. The registered enrollment target is 38 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03987464, a NA study of Mild Cognitive Impairment, has completed, sponsored by Allison Gibson.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The process of receiving a diagnosis of mild cognitive impairment (MCI) is recognized to induce behavioral responses that can be either adaptive or maladaptive. Five specific areas of concern have been identified, including: 1) failure to plan for future decline, decreased compliance and interaction with medical care providers, 3) decreased confidence and reduced social engagement, 4) increased physical limitations and 5) decreased medication compliance. In this pilot study, participants with MCI and their study partners will participate in behavioral interventions (primarily training workshops and classes) targeting each of these five areas of potential maladaptive behaviors.
Primary Outcome
The general self-efficacy scale (GSES) is a ten-item scale. Scores range from 10-40, with higher scores indicating more self-efficacy.
Conditions Studied
Interventions
- BEHAVIORAL Planning for the Future
- BEHAVIORAL Enhanced Medical Engagement
- BEHAVIORAL Confidence Building and Social Engagement
- BEHAVIORAL Physical Intervention
- BEHAVIORAL Medical Adherence
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2021-12-14 |
| Phase | NA |
What the finished NCT03987464 record still lists
NCT03987464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 5 interventions - of which Planning for the Future is the first listed.
NCT03987464 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03987464 about?
NCT03987464 is a clinical study titled "Platform-based Mild Cognitive Impairment (MCI) Trial". The process of receiving a diagnosis of mild cognitive impairment (MCI) is recognized to induce behavioral responses that can be either adaptive or maladaptive. Five specific areas of concern have been identified, including: 1) failure to plan for future decline, decreased compliance and interaction...
What is the current status of trial NCT03987464?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2019-11-01. Estimated completion is 2021-12-14.
What conditions does trial NCT03987464 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT03987464?
The interventions under investigation include: Planning for the Future (BEHAVIORAL), Enhanced Medical Engagement (BEHAVIORAL), Confidence Building and Social Engagement (BEHAVIORAL), Physical Intervention (BEHAVIORAL), Medical Adherence (BEHAVIORAL).
Who is sponsoring clinical trial NCT03987464?
This trial is sponsored by Allison Gibson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03987464 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03987464's enrollment target sits among peer trials
38 155th of 205 higher than 50 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Impact of Intensive Computerized Cognitive Training
RECRUITING · NA
-
Multimodal Investigation of Neural Plasticity
RECRUITING · NA
-
GAMES Intervention in MCI (Mild Cognitive Impairment)
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI